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Chapter 13: Development of the Personal Genomics Industry 
 
By Jorge L. Contreras, J.D. and Vikrant G. Deshmukh, Ph.D., J.D. 
 
Today, numerous commercial services offer genetic testing, genotyping and 
genome sequencing services both to medical providers and directly to the public.  
Twenty-five years ago, such offerings would have been unthinkable, both in terms of cost 
and medical practice.  This chapter describes the development of the personal genomics 
industry and its evolving business models and goals. 
 
Introduction 
 A recent study found that, between the beginning of the Human Genome Project 
in 1990 and 2004, 470 different private firms in 25 countries began to offer products and 
services based on genomic technology or data (Wiechers, Perin, & Cook-Deegan, 2013).  
These commercial offerings included the sale of genome sequencing equipment and 
reagents, the development of drugs and vaccines using genomic data 
(pharmacogenomics), testing for disease susceptibility, and a host of data-driven 
applications (Wiechers et al., 2013).  Researchers at the Battelle Memorial Institute have 
estimated (Battelle, 2013) that by 2012, more than 47,000 individuals in the U.S. alone 
were employed by the genomics industry, which they divide into six primary sectors 
(bioinformatics, testing, reagents, instrumentation, R&D and pharmacogenomics).  Thus, 
although the commercial genomics industry has existed for only twenty-five years, it is 
large and complex, with widely varying product offerings, business models and 
strategies.   
 In this chapter, we focus only on those segments of the commercial genomics 
industry that offer products and services to end user consumers, either directly or through 
intermediaries such as physicians, genetic counselors or testing laboratories, a sector that 
we collectively refer to as “personal genomics” (Khoury et al., 2009).  Our focus will 
further be limited to those products and services that provide genetic or genomic 
information to consumers, as opposed to drugs, vaccines or treatment regimens that may 
have been discovered using genomic information, or the administration of which may be 
influenced by a recipient’s genomic characteristics. But even limited thus, the field is 
complex and multifaceted. 
 
Genetics and Genomics 
 Each strand of human DNA consists of approximately 3.2 billion paired 
nucleotide bases, the sum of which is referred to as the human “genome.”  Some fraction 
of these bases is organized into contiguous sub-units called “genes,” ranging in size from 
 Electronic copy available at: https://ssrn.com/abstract=3092313 
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as few as a hundred to more than two million base pairs. It is currently estimated that 
human DNA contains approximately 20,000 genes. Genes are responsible for the 
inheritance of traits from one generation to the next and encode the many proteins 
responsible for biochemical functions within the cell. Each human genome is 
approximately 99.9% identical, and very small differences account for much of the 
variability in human physical and physiological traits (Feuk, 2006; NHGRI, 2014a), 
along with epigenetic variation (Issa, 2002).   
  While hypotheses regarding the existence of biochemical mechanisms for the 
heredity of human traits have existed since the nineteenth century, it was not until 
Watson and Crick’s landmark discovery of the structure of DNA in 1953 that modern 
genetics was born. Throughout the 1960s and 1970s genetic studies became increasingly 
sophisticated, until by the mid-1970s, technology had evolved to a point at which 
researchers could begin to identify individual genes responsible for diseases such as 
Cystic Fibrosis and Huntington’s disease (MacDonald, 1993; Rommens, 1989).  Even so, 
each of these discoveries took years of painstaking work and a measure of good luck to 
achieve. In 1983 a revolutionary new process for determining the order of bases within a 
DNA molecule emerged.  This process, called the Polymerase Chain Reaction (PCR), 
enabled researchers to unravel the genetic code of humans and many other organisms 
more efficiently (Mullis, 1987), and earned its inventor, Kary Mullis at Cetus 
Corporation, the Nobel Prize.  
 The advent of PCR technology soon gave rise to an ambitious plan to sequence 
not only genes identified with specific diseases, but the entire human genome (Watson & 
Jordan, 1989).  The decision by the U.S. government to form an international consortium 
to undertake this monumental project in the late 1980s signaled the birth of the field now 
known as genomics, the study not of individual genes, but of the entire genome. 
 
The Human Genome Project and Data-Driven Business Models 
 For most of the twentieth century, the bulk of genetic research was carried out at 
academic institutions and government laboratories.  The scale, sophistication and 
speculative nature of such research generally made it unattractive to commercial 
enterprises well into the first decade of the twenty-first century.  The Human Genome 
Project (HGP) was officially launched in 1990 as a joint project of the U.S. National 
Institutes of Health (NIH) and the U.S. Department of Energy (DOE), with support from 
the Wellcome Trust in the United Kingdom and funding agencies in the United Kingdom, 
France, Germany and Japan.  
 The initial stages of the HGP were devoted to refining the instrumentation needed 
to sequence the human genome and undertaking pilot sequencing projects on simpler 
organisms such as the E. coli bacterium (Durham, 1997).  By 1998, after the expenditure 
of nearly $2 billion, the HGP prepared to begin work on the human genome.  Then, in 
May of that year, J. Craig Venter, a former NIH scientist, famously proclaimed that he, 
with substantial commercial backing, would utilize state-of-the-art equipment, together 
with much of the HGP’s publicly-released data, to sequence the entire human genome in 
only three years, a full four years before the HGP was scheduled to complete its work 
(Wade, 2000).  Venter’s announcement sent a shock wave through the genomics 
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community and led to a widely publicized “arms race” between his new company, Celera 
Genomics, and the HGP (Roberts, 2001). 
 Ultimately, a truce was brokered by the journal Science (Jasny, 2013) and, in June 
2000, Francis Collins, the leader of the HGP and Venter were invited to the White House 
to announce jointly that a “first draft” of the human genome had been completed (Wade, 
2000).  In his remarks, President Clinton emphasized the role of commercial enterprises 
in the new field of genomics, declaring that “[w]e must discover the function of these 
genes and their protein products, and then we must rapidly convert that knowledge into 
treatments that can lengthen and enrich lives.  I want to emphasize that biotechnology 
companies are absolutely essential in this endeavor” (Clinton, 2000). 
 Unlike the public HGP, Celera’s goal in sequencing the human genome was not to 
release genomic data to the public, but to profit from licensing this data to pharmaceutical 
and biotechnology companies.  Like many companies, Celera sought to facilitate the 
emerging pharmacogenomics industry, which, it was hoped, would develop new and 
more effective drugs and vaccines guided by genomic information.  Thus, while the 
public HGP regularly uploaded its DNA sequence data to the public GenBank database 
maintained by the U.S. National Library of Medicine, Celera made its data available 
solely on its commercial web site.  The company allowed scientists from non-profit and 
academic institutions to access the data without charge, but required researchers who 
wished to use the data for commercial purposes to enter into a license agreement 
(Marshall, 2000). 
 Celera’s approach outraged much of the scientific community and led to a highly 
publicized debate over private ownership of human genome data (Marshall, 2000).  When 
Celera and the HGP announced the completion of their first drafts of the human genome 
in 2000, Celera committed that it would make its data broadly available, though it still 
required payment by commercial users (Marshall, 2001b).  Celera’s subscription-based 
data business was ultimately unsuccessful and, in 2005, the company exited the business 
and released its genomic data to GenBank (Kaiser, 2005).  It is likely that Celera’s data-
driven business failed, in large part, due to the competing public efforts that released 
large quantities of similar, if not identical, data to the public.   
 In the 1990s Celera was just one of several firms that attempted to capitalize on 
potentially profitable uses of genomic sequence data.  Even before the completion of the 
human genome project, firms including Incyte Pharmaceuticals in Palo Alto, California, 
and Human Genome Sciences in Rockville, Maryland, were actively pursuing a business 
strategy of patenting, and seeking to license, short gene sequences known as expressed 
sequence tags (ESTs) and other genetic data (Marshall, 2001a).  By the time the first EST 
patent was issued to Incyte in 1998, that company alone had filed patent applications 
claiming more than 1.2 million DNA sequence fragments (Murry, 1999).  These early 
efforts were eventually thwarted by a combination of factors including judicial and 
administrative decisions limiting the patentability of ESTs (Demaine, 2002), as well as 
earlier efforts to place large quantities of similar EST data into the public domain.  The 
most notable of these earlier efforts was the “Merck Gene Index,” a project led by 
pharmaceutical giant Merck in collaboration with Lawrence Livermore National 
Laboratory and Washington University (Contreras, 2011).  By 1998, the Merck Gene 
Index had released over 800,000 ESTs through GenBank, substantially limiting the 
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ability of companies to license the same or similar data to the pharmaceutical industry in 
a profitable manner.   
 A similar effort known as the SNP Consortium was conducted in conjunction with 
the HGP by a group of pharmaceutical and information technology companies, with 
additional support from the Wellcome Trust.  The SNP Consortium sponsored research to 
identify and map genetic markers referred to as “single nucleotide polymorphisms” 
(SNPs), which it then released to the public domain (Holden, 2002; Contreras 2011).  
SNPs are common genetic variations that occur throughout a person’s DNA, some of 
which are important in the study of human health (Genetics	Home	Reference, 2014a).  
The SNP consortium ultimately mapped 1.4 million SNPs, all of which were free from 
patents and made publicly accessible without charge.   
 It is likely that public data release efforts by the HGP and associated private 
sector projects such as the Merck Gene Index and the SNP Consortium limited the market 
for general purpose genomic databases, though, as we discuss below, there may still be 
substantial value in mutation databases associated with particular diseases. 
 
The Genetic Testing Sector  
 The business models discussed in the section above were based on the private 
generation or collection of large quantities of genomic data, with the goal that this data 
then be licensed on a commercial basis to pharmaceutical and biotechnology companies 
engaged in pharmacogenomics research.  A different business model developed from 
more narrowly-focused efforts to identify genetic mutations associated with particular 
diseases.  As of this writing, more than 37,000 different genetic tests are available from 
1,600 laboratories and clinics in the U.S. for nearly 4,000 genetic disorders (GeneTests, 
2014).   The vast majority of these genetic tests are available to patients only through a 
physician or clinical setting. 
 The first disease-specific genetic test was developed for Cystic Fibrosis, a 
debilitating condition that affects approximately 30,000 children and adults in the United 
States, and 70,000 worldwide (Cystic	Fibrosis, 2014).  A mutation in the CFTR gene that 
is strongly correlated with Cystic Fibrosis was discovered in 1989 by teams at the 
University of Michigan, Johns Hopkins University and the Hospital for Sick Children in 
Montreal.  The discovery was patented, but each of the institutions holding patent rights 
elected to license its rights on a non-exclusive basis (meaning that the patent holder 
permitted multiple laboratories to perform testing, rather than only a single laboratory) 
(Chandrasekharan, Heaney, James, Conover, & Cook-Deegan, 2010).  As a result, in 
2009 sixty-three different labs in the United States performed testing for CFTR mutations 
at relatively affordable prices (ibid.). 
 A different market structure developed with respect to tests in which controlling 
patents were licensed on an exclusive basis.  For example, Athena Diagnostics of 
Marlborough, Massachusetts has exclusive rights to exploit patents covering genetic 
diagnostic tests for mutations of several genes associated with hearing loss and 
Alzheimer’s disease.  In the case of the APOE gene, whose particular variants are 
associated with late-onset Alzheimer’s disease, Athena holds an exclusive license from 
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Duke University and has actively sought to prevent other laboratories from offering 
testing based on this mutation (Skeehan, Heaney, & Cook-Deegan, 2010).  One exception 
arose in 2008, when Athena licensed a small company called Smart Genetics to offer 
APOE testing directly to consumers via a mail-in kit in conjunction with telephone 
consultation.  But Smart Genetics discontinued its APOE testing program after only a few 
months, apparently following the intervention of Duke University (Skeehan et al., 2010). 
 The best-known example of commercial genetic testing is probably that of Myriad 
Genetics.  Strong correlations between mutations in the BRCA1/2 genes and 
breast/ovarian cancer in certain populations were identified in the early 1990s by research 
groups at the University of Utah and the U.S. National Institutes of Environmental Health 
Sciences (NIEHS) and two corporations: Myriad and Oncormed, Inc..  Myriad eventually 
obtained control over the patents covering the most significant BRCA mutations and 
elected not to license third parties to perform testing.  As a result, by 2000 Myriad was 
the only U.S. laboratory performing full BRCA testing, for which it charged 
approximately $3,000.  Controversy arose due to the cost of Myriad’s test and the fact 
that many U.S. healthcare payors, including the federal Medicare system, declined to 
cover BRCA testing costs in many cases.  Myriad’s assertion of exclusive rights in the 
BRCA testing market led a coalition of patients, advocacy groups, physicians and clinics 
to mount a legal challenge against Myriad’s patents in 2009.  The case led to a landmark 
2013 decision by the U.S. Supreme Court invalidating all of the challenged patent claims 
and establishing that DNA sequences occurring in the human body are not eligible for 
patent protection in the U.S. (Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 
2013).  
 Shortly after the Myriad ruling, a number of additional firms, including laboratory 
giants Ambry Genetics and Laboratory Corporation of America, entered the market for 
BRCA testing by offering tests at significantly lower price points than Myriad (Ambry, 
2013; LabCorp, 2013).  At this writing, Myriad is engaged in litigation seeking to enforce 
a new set of patents against these and other firms. 
 The degree to which Myriad will impact patents held by Athena and other 
diagnostic testing companies, and its overall effect on the genetic testing industry in the 
U.S., is still unclear. Several commentators believe that single-gene patents of the type 
held by Myriad and others would, in any event, be of little use to exclude competitors 
from performing whole genome sequencing and other tests that involve more than the 
isolation of single genes (Rai & Cook-Deegan, 2013).  
 Outside of the U.S., patents covering genetic testing appear to be on more solid 
footing.  The Australian Supreme Court, for example, recently upheld a number of 
Myriad’s patents covering BRCA mutations ("Cancer Voices Australia v Myriad Inc 
[2014] FCAFC," 2014).  The crux of the dispute was whether isolated DNA including 
complementary DNA (cDNA) was patent eligible.  In holding both varieties of DNA to 
be patentable, the Australian Court arrived at a different conclusion than the U.S. 
Supreme Court, which had held that isolated DNA was not patent eligible because it was 
a product of nature.  In Europe, Myriad’s BRCA1 and BRCA2 patents were challenged 
and substantially upheld by the European Patent Office (EPO).  However, during 
successive proceedings, the claims were reduced in scope from the entire BRCA1 gene 
sequence to individual mutations, cloning vectors and host cells, and methods for 
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detecting mutations in BRCA2 (Matthijs, Huys, Van Overwalle, & Stoppa-Lyonnet, 
2013).  The resulting claim scope in Europe is substantially narrower than in either the 
U.S. or Australia. 
 
Direct-to-Consumer (DTC) Genomics 
Following the completion of the Human Genome Project, rapid advances in gene 
sequencing technology coupled with a precipitous drop in the price of sequencing 
equipment, led to the emergence of a new market: direct-to-consumer (DTC) genomic 
testing.  DTC genomics vendors offer services directly to the public, typically without the 
involvement of a healthcare provider.  These services typically involve the consumer’s 
submission of a DNA sample (usually a saliva swab) to a designated facility, and the 
vendor’s performance of one of three types of analysis: genotyping, exome sequencing or 
whole genome sequencing (see Kornilov, this volume).   
The process of scanning a genome for known genetic markers or SNPs is called 
genotyping.  Genotyping is typically performed by comparing a sample of human DNA 
to known markers on a commercially available panel or “chip”.  Vendors such as 
Illumina currently offer genotyping panels that contain over one million known markers.  
The presence or absence of the tested markers can support inferences about the subject’s 
risk for certain diseases, ancestry and physiological characteristics.   
While genotyping can offer a substantial amount of information to consumers, 
even the largest million-marker chips contain only a tiny fraction (i.e. 0.03%) of the 3.2 
billion base pairs comprising the full human genome. Sequencing the entire genome of an 
individual (whole genome sequencing) is a much larger task.  The HGP spent 
approximately $3.8 billion over a decade to sequence the genomes of multiple individuals 
to develop a common genomic profile for human species.  The cost of genome 
sequencing has dropped precipitously in the years since the completion of the HGP.  For 
years, the “holy grail” of genome sequencing has been the $1,000 genome: the ability to 
sequence an entire human genome for a cost of only $1000 (Davies, 2010).  The National 
Human Genome Research Institute (NHGRI) tracks costs associated with whole genome 
sequencing at centers that it funds, and most recently estimated that this cost had dropped 
to between the $4,000 and $5,000 (Wetterstrand, 2014).  And in 2014, Illumina 
announced that it “broke the sound barrier” of human genomics by enabling the $1000 
genome with a new sequencing platform (Illumina, 2014).  Nevertheless, it is likely that 
the $1000 genome still remains a few years away for the average consumer.   
Meanwhile, companies like Gene by Gene offer a middle-road between 
genotyping and whole genome sequencing in the form of exome sequencing, which 
involves sequencing only those protein-coding fragments of an individual’s genome.  
These 19,000 or so protein-coding regions represent about 1% of the entire human 
genome (Ng et al., 2009), but can support medically valuable incidental/secondary 
findings (Green et al., 2013).  Thus, exome sequencing avoids the high cost of whole 
genome sequencing, while offering more information than genotyping.   
 
Ancestry Information 
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Genetic ancestry testing (GAT) or genetic genealogy relies on an examination of 
variations in DNA to infer where a person’s ancestors may have originated (Genetics	
Home	Reference, 2014b).  GAT is based on the idea that closely related individuals, 
families or populations share more genetic variations with one another.  GAT can 
complement traditional genealogical research by providing missing pieces of ancestry 
information, but cannot itself provide detailed information about specific ancestors.  
One of the first organizations to offer GAT to the public was the Genographic 
Project, a collaboration between the National Geographic Society and IBM.  The 
Genographic Project began to distribute genetic testing kits in 2005 for a $99 charge 
(Davies, 2010).  The Project gave its participants information regarding their likely 
ancestry, along with historical perspectives on the migration paths followed by ancient 
peoples (Wells, 2005).  The kits are still offered for $99, and at the time of this writing 
over 688,000 individuals from more than 140 countries have participated in this project.   
A number of additional commercial GAT tests are offered for approximately $99 
by companies including 23andMe, Ancestry.com DNA and Family Tree DNA. 
(23andMe, 2014a; Ancestry, 2014; Family	Tree	DNA, 2014).  
 
Nutritional Genomics 
The field of nutritional genomics pertains to interactions between genes and the 
environment, particularly nutrients, chemicals, and other matter introduced into the body 
as part of dietary food consumption (Dudley, 2013).  For example, Familial 
Hypercholesterolemia (FH), a condition characterized by severely elevated LDL 
cholesterol and increased risk of coronary artery disease, can be traced to mutations in the 
APOB, LDLR and PCSK9 genes.  Individuals who carry these mutations are managed 
medically by a combination of diet and lifestyle changes, along with pharmacotherapy 
(Youngblom, 2014).  
Some companies have tried to capitalize on public interest in nutritional genomics 
through consumer testing products.  For example, Evidence Based Nutrition (EBN) based 
in Chula Vista, California, offers customers a “DNA Nutrition Action Plan” that “makes 
nutritional and lifestyle recommendations based on an understanding of the individual’s 
unique genetic profile” (Spicer, 2008).  EBN primarily sells nutritional supplements.   
Sciona, Inc., headquartered in Aurora, Colorado, offers the MyCellf test, which it 
claims to be “designed to provide dietary and lifestyle recommendations gleaned from 
individual genetic data” (Davies, 2010). Author Kevin Davies took the MyCellf test and 
reported that Sciona recommended that he get more exercise, cut back on alcohol and 
caffeine, and increase his daily intake of vegetables (ibid.).  Predictably, claims such as 
these from nutrigenetic testing firms have been criticized for being too generic at best, 
and at times misleading (Kutz, 2006).  
 
DTC and Health Information  
While using genomic information to provide information about ancestry and 
nutrition has commercial potential, these applications pale in comparison to the detection 
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of health-related information hidden within the genomes of consumers. Home-based 
genetic paternity testing, as well as genetic testing for specific health conditions, have 
been available for years.  Only with the increasing accessibility of genotyping and 
genomic sequencing, however, have consumers had the opportunity to obtain large 
quantities of data regarding their genomic make-up and its potential health implications. 
In 1998, deCODE genetics, a Reykjavík, Iceland based biopharmaceutical 
company, lobbied for and won exclusive rights to revamp Iceland’s national health record 
system, which included records containing patient diagnoses, treatments, results, 
complications, etc., as well as biospecimens, genotypes and genealogical records for the 
entire nation (Chadwick, 1999).  deCODE discovered several genes associated with 
diseases in humans, and offered lab tests for various disease genotypes, in collaboration 
with Hoffman-LaRoche, Merck, and others, although a majority of these tests were not 
marketed to consumers.   
In 2007, deCODE launched a web-based DTC genomics service called 
deCODEme, which was the first commercial offering of its kind. For less than $1,000, 
deCODE would analyze approximately 600,000 sites in a customer’s DNA having a 
known influence on both common physical traits such as baldness, eye color and tongue-
rolling, as well as risk for certain diseases including diabetes and several cancers (Davies, 
2010).  DeCODE conceptualized its offering as an educational service rather than a 
medical diagnostic, explaining “[w]e are not providing people with a genetic test.  We are 
only allowing them to compare their genomes to the genomes of those who in the 
literature have been described as having a risk of a disease.  We encourage people not to 
make medical decisions on the basis of results of this, but we point people to the 
possibility of taking results of this to their doctors…” (Davies, 2010). 
In 2006, David Agus, an oncologist, and Dietrich Stephan, a neuroscientist, 
founded Navigenics, Inc.  Navigenics offered DTC tests for eighteen common illnesses 
including diabetes, heart disease, obesity and certain cancers (Davies, 2010; Hall, 2007).  
One of the distinguishing features of Navigenics’s approach was its heavy emphasis on 
genetic counseling.  Recognizing the complexity and sensitive nature of individual 
genomic information, Navigenics required a “telephone consult” with one of its genetic 
counselors before giving a customer full access to his or her DTC testing results.  
Customers could also download their raw genomic data after signing a waiver. 
The best-known purveyor of DTC genomic testing today is probably 23andMe, a 
California-based company founded by Linda Avey, Paul Cusenza and Anne Wojcicki in 
2006 (23andMe, 2014a).  In November 2007, 23andMe joined deCODE and Navigenics 
in offering the public DTC testing that included ancestry and health information 
(Hanahan, 2007).  Wojciki, the spouse of Google co-founder Sergey Brin, explained, 
“23andMe is designed to provide our customers with scientifically accurate, high-quality 
information about their own genetic code in a format that is easy to understand and use.”  
23andMe’s bold approach and knack for publicity quickly grabbed the public 
imagination, and Time Magazine named it the 2008 ‘Invention of the Year’ (TIME 
Magazine, 2008).  23andMe has also attracted investment from other pharmaceutical and 
biotechnology companies since its founding, and recently announced a $60 million deal 
with biotech giant Genentech.  A significant aspect of this investment will give 
Genentech access to the 23andMe database containing genotypic records of over 800,000 
Contreras and Deshmukh  Page 9 
customers (Herper, 2015).  In February 2015, the U.S. Food and Drug Administration 
(FDA) allowed 23andMe to market the first DTC genetic carrier test for Bloom syndrome  
(U.S. Food and Drug Administration, 2015), a rare genetic disorder characterized by 
short stature and increased predisposition to cancer. 
Even independently of 23andMe, Google’s interest in the field of genomics is not 
to be underestimated.  In February 2014, the Internet giant launched Google Genomics, a 
web-based application for importing, storing, searching, analyzing and sharing individual 
genomic data (Gruber, 2014).  Harvard professor George Church predicts that Google’s 
data mining software will open “huge new markets in wellness and precision medicine 
(ibid.).”   
Alongside these purveyors of broad spectrum DTC genomic information are 
numerous smaller firms that offer genotyping for specific non-disease traits.  Among 
these is Richmond, Virginia based American International Biotechnology, which offers a 
$200 test kit that “provides athletes and parents of young sports competitors a wealth of 
information about their athletic strengths” (AIBioTech, 2011).  Some in the scientific 
community have questioned the validity of the conclusions that can be drawn from such 
information, and have criticized the marketing approach taken by AIBioTech and others 
(Collier, 2012). 
 
Comparing DTC Offerings 
With at least three major DTC personal genomics options available to consumers 
by the late 2000s, it became important to clarify how these services differed from one 
another. Whereas 23andMe took a self-service approach in providing the consumer with 
large quantities of easy-to-use information, Navigenics and deCODE preferred that 
consumers interact with genetic counselors to interpret their results.  And while 23andMe 
offered more information on complex traits, deCODE offered greater contextual 
information for data relating to ancestry (Davies, 2010). 
The similarities and differences among DTC genomics offerings also became the 
object of scientific study.  One such study found over 99.6% concordance in the SNP 
genotypes provided by deCODE, 23andMe and Navigenics (most likely because they all 
used the same commercial genotyping technology), but noted large variations in the 
analysis of risks reported by these companies (Imai, Kricka, & Fortina, 2011). For 
example, one study found that the relative risks for rheumatoid arthritis that the 
companies reported ranged from 0.9 to 1.85, i.e. from having a protective effect to having 
a deleterious effect (ibid.).  Similar findings were observed in other studies, and the 
differences were attributed, among other things, to the methods used in characterizing the 
underlying populations (Kalf et al., 2014).   
While academic studies have provided a scientific comparison of DTC services, 
members of the media have also reported their experiences with DTC testing (Dickinson, 
2008). Journalist Boonsri Dickinson, for example, compared her DTC test results from all 
three companies and received surprisingly divergent results.  Having both Asian and 
European ancestry, she discovered that the risk information provided by the test vendors 
varied widely depending on whether she identified herself as belonging to one ethnic 
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group or the other.  Such critiques have cast increasing doubt on the usefulness and 
informative value of many DTC genomic services. 
Whole Genome Sequencing for All? 
Around the time that deCODE, 23andMe, and Navigenics were marketing DTC 
genomic tests based on known markers, others, like Harvard professor George M. 
Church, ventured in a different direction.  Church was one of the first individuals to have 
his entire genome sequenced and joined other notable figures such as James Watson in 
releasing his genomic data to the public.  Church founded Knome Inc. in 2007 to offer 
whole genome sequencing services to the general public, “on the recognition that the 
rapidly falling price of whole genome sequencing would create substantial market need 
for whole genome interpretation technologies and services” (Knome, 2014).  Today, that 
vision has largely been realized; indeed, when Knome first offered whole genome 
sequencing, it cost a hefty $350,000, whereas more recent cost estimates are in the $6,000 
range (Eisenberg, 2013).   
Other notable companies in the whole genome sequencing arena included Helicos 
Biosciences and Complete Genomics.  Helicos was founded in 2003 by Stephen Quake 
from the California Institute of Technology, and Stanley Lapidus and Noubar Afeyan of 
Flagship Ventures.  Helicos specialized in a novel technique known as Single Molecule 
Sequencing, which allowed the sequencing of a single DNA molecule without the need 
for PCR, and offered an advantage over second-generation sequencing techniques at the 
time (Thompson & Milos, 2011).   
Complete Genomics was founded by Clifford Reid and Radoje (Rade) Drmanac 
in 2006.  In 2009 the company began to offer whole genome sequencing services not to 
consumers, but to pharmaceutical and biotechnology companies and academic medical 
centers at a cost of approximately $5,000 per genome (Lauerman, 2009).  While Knome 
and Complete Genomics continue to offer whole genome sequencing services as of this 
writing, Helicos filed for bankruptcy in 2012.  
The potential of DTC whole genome sequencing is significant.  What cost the 
HGP $3.8 billion to produce over ten years could soon be available to every man, woman 
and child for less than $1,000 through a mail-in kit.  The greatest challenge of DTC 
whole genome sequencing is how to interpret the vast quantity of genomic data that will 
be delivered to consumers.  Modern science has only scratched the surface of 
understanding the myriad functions of the 3.2 billion base pairs that constitute the human 
genome.  It will likely be many years before scientific understanding catches up with the 
technical ability to generate whole genome sequence data.  
 
Market Shake-out for DTC Vendors 
The financial crisis of 2008 put an enormous strain on many industries, and 
several DTC genomics providers went out of business.  In November 2009, two years 
after initially offering its DTC service, deCODE filed for bankruptcy.  deCODE got a 
fresh start in 2012, when it was acquired by biotech giant Amgen (Amgen, 2012).  It is 
not clear, however, whether Amgen will restart deCODE’s DTC genomics service, or 
simply use the Icelandic company’s genetic resources and database to support its existing 
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drug discovery and development businesses.  In 2012, Navigenics also ceased to offer 
DTC genomic services after being acquired by Life Technologies, a subsidiary of 
equipment manufacturer Thermo Fisher Scientific.  Whereas both deCODE and 
Navigenics struggled, 23andMe has flourished, attracting over $100 million in investment 
from the likes of Google, Johnson and Johnson, and Genentech, and major private 
investors such as Google co-founder Sergey Brin and Digital Sky Technologies co-
founder Yuri Milner (CrunchBase, 2014).  
Governmental Scrutiny of DTC Testing 
In 2004, the American College of Medical Genetics issued a statement that 
“genetic testing should be provided to the public only through the services of an 
appropriately qualified health care professional,” warning that “the self-ordering of 
genetic tests by patients over the telephone or Internet [could result in harms including] 
inappropriate test utilization, misinterpretation of test results, lack of necessary follow-
up, and other adverse consequences” (ACMG, 2004).  This perspective has shaped the 
policy debate over DTC genomic services in the United States, and has led to significant 
intervention by state legislatures and federal agencies over the DTC genomics industry. 
In the United States, state governments are generally responsible for regulating 
consumer health and safety, as well as the practice of medicine and licensure of 
healthcare providers within their borders.  Depending on the state, laws and regulations 
may either expressly permit genomic DTC testing, ban such services outright, impose 
partial regulations or remain silent on the issue (Dick, 2012; Berman, 2007).  Illustrating 
this range of regulatory regimes, Virginia explicitly allows direct reporting of DTC 
genomic results to individuals, California and New York require physician authorization, 
and Colorado and Utah classify DTC genomic testing outside the practice of medicine 
and thus beyond state licensure regulation (Dick, 2012).  
In 2008, both California and New York began to require medical licensing for 
DTC genomics vendors and sent cease and desist letters prohibiting further sales to 
consumers without medical oversight (Langreth, 2008; Magnus, Cho, & Cook-Deegan, 
2009; Pollack, 2008).  The targeted DTC companies objected, arguing that patients had a 
right to receive their genetic information, that genetic testing is not diagnostic or medical 
in nature, and that patients deserved direct access to testing without a physician 
intermediary (Magnus et al., 2009).  Nevertheless, most DTC companies eventually 
complied with state demands and stopped accepting DNA samples from New York and 
California (Pollack, 2008). 23andMe, however, took a creative approach, still shipping 
kits to consumers in New York, but requiring them to “affirm under penalty of law that 
the sample for the saliva kit has not been collected in or mailed from the state of New 
York” (23andMe, 2014b).  On the other hand, in 2010, Navigenics became one of the 
first DTC genomics companies to obtain a New York Clinical Laboratory Permit 
(Sweeney, 2010).  
The U.S. federal government has also shown an interest in the activities of DTC 
genomics vendors.  In 2006 the U.S. Government Accountability Office (GAO) launched 
an investigation of the practices of several DTC companies, and concluded in a 
subsequent investigation that they provided “medically unproven disease predictions” (G. 
Kutz, 2010).  GAO’s investigation involved the purchase of DTC tests by a number of 
Contreras and Deshmukh  Page 12 
fictitious consumers.  These test subjects received disease and risk predictions that varied 
across four DTC companies for the same DNA samples, and contradicted known family 
history and other traits in the DNA donors. 
DTC genetic testing is subject to the jurisdiction of at least three separate Federal 
regulatory agencies: the Federal Trade Commission (FTC), the Centers for Medicare and 
Medicaid Services (CMS), and the Food and Drug Administration (FDA)(NHGRI, 
2014b).   
The FTC regulates consumer protection and polices false and misleading 
advertising under the Federal Trade Commission Act.  There have been numerous 
critiques of consumer DTC genomics advertising, pointing to its potential distortion of 
DTC testings’ risks and benefits, its limited educational value and its potential for 
disseminating misinformation to the public (Gollust, Hull and Wilfond, 2002).  As a 
result, the FTC has scrutinized DTC genomics advertising and has issued a consumer 
advisory on its website about DTC genetic tests, alongside other cautionary articles about 
“miracle health claims” and “cancer treatment scams” (Federal Trade Commission, 
2014).  
CMS regulates clinical laboratory testing (excluding research) throughout the 
U.S. under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, which 
covers the educational requirements, quality control and proficiency testing of individual 
labs. In order to offer medical tests to the public and return results to consumers, 
laboratories performing DTC genomic testing must have an appropriate CLIA certificate 
(CMS, 2014).   
Separately from CMS’s regulation of clinical laboratories, the FDA regulates 
medical devices marketed in the U.S. under the Medical Devices Amendments to the 
Federal Food, Drug and Cosmetic Act.  FDA’s broad oversight of medical devices has 
been argued to extend to laboratory-developed tests and test kits, as well as related 
software (Javitt & Carner, 2014).  
In 2009, the FDA, which had become increasingly concerned about the 
distribution of genomic diagnostic information by unregulated DTC vendors, began to 
seek more information regarding DTC practices and tests.  The major DTC genomics 
vendors largely sidestepped the FDA’s inquiries, and matters came to a head in the 
summer of 2010, when the FDA issued warning letters to several vendors including 
23andMe, Navigenics, and deCODE (U.S. Food and Drug Administration, 2010).  
According to the FDA, the kits and services offered by these vendors fell under the 
Medical Devices Amendments, and these firms had neither filed for premarket approval, 
nor notified the agency of their intent to commercially distribute the respective devices. 
On this basis, the FDA ordered these companies to discontinue marketing DTC genomic 
services until they received marketing authorization from the FDA, and to provide 
documentation about specific corrective actions they had undertaken to address these 
issues (ibid.). 
As a result of the FDA’s actions, in December 2013, 23andMe announced that it 
was discontinuing the ‘23andMe Health’ personal genomics service, which had provided 
consumers with health-related interpretive information along with the results of its 
genotyping analysis, pending an FDA regulatory review (Afarian, 2013).  23andMe 
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switched instead to providing its customers with raw SNP data (i.e., the actual genotypic 
test results indicating the presence of particular SNPs at particular locations along the 
genome), along with ancestry information.  Other DTC companies that offered similar 
tests followed suit, limiting their offerings to raw SNP data and leaving consumers to 
perform their own interpretations.   
Despite the current unavailability of interpretive or health information from DTC 
vendors, consumers who obtain SNP and other raw genomic data about themselves are 
not without options.  Free software tools such as Promethease (Promethease, 2014) can 
generate personal genomics reports using raw sequence data based on publicly available 
scientific literature in the public SNPedia (Cariaso & Lennon, 2012; SNPedia, 2014).  
Promethease can import data directly from the reports offered by vendors such as 
23andMe, and can also decipher raw data files that most DTC vendors provide to 
consumers.  The actual process involves matching raw SNP data with known SNPs in 
SNPedia, and using that knowledge base to generate meaningful interpretation.  Other 
websites such as interpretome.com (Karczewski, 2012), livewello.com (Livewello, 2015), 
and geneticgenie.org (Genetic Genie, 2015) also offer “interpretation-only” services for 
DTC tests similar to Promethease.  Due to the rapid pace of discovery and the relative 
newness of these services, there is no gold standard. Nevertheless, one recent study found 
Promethease results to be among the most detailed, although not as user-friendly as the 
services originally offered by 23andMe (Regalado, 2014).  Ultimately, the accuracy of 
these tools is only as good as the underlying data sources.  SNPedia, for instance, has at 
least four levels of data curation, three of which are directly performed on the database 
itself, whereas an additional fourth level of review is dedicated to the content used by 
Promethease, and helps screen errors in original research in the original data-sources 
(Cariaso & Lennon, 2012). 
Personal Genomics outside the U.S. 
Though, with the exception of deCODE in Iceland, the personal genomics 
initiatives of U.S. firms have received most of the attention from the Western press, such 
efforts are not limited to the U.S. market.  Regulators around the world have weighed the 
benefits and risks of genetic testing, including DTC, for several years, and legal 
developments in Europe bear striking similarities to those in the United States.  In 2008, 
following the approval of protocols related to genetic testing by the Committee of 
Ministers of the Council of Europe, some speculated that Europe might move toward 
banning DTC testing altogether (Borry, 2008).  In 2009, Germany enacted legislation that 
effectively banned DTC genomic services by requiring that genetic tests be carried out 
exclusively by a physician following informed patient consent (The Associated Press, 
2009).  France, Portugal and Switzerland have similar legislation restricting DTC 
genomics, while the Netherlands only has limited restrictions on genetic tests for 
detecting “incurable diseases” (Borry et al., 2012).  The United Kingdom and Belgium 
currently have no specific restrictions on DTC genomic testing (ibid.).  
In the EU, DTC testing is currently covered by European Directive 98/79, which 
proposes objectives, but is not directly binding on member states, many of which have 
national legislation that covers these tests (Kalokairinou,	2014).  However, a new 
proposed regulation, if adopted by the EU, would be binding on member states.  The 
regulation proposes a risk-classification system for medical devices including DTC tests.  
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It further provides that agencies must evaluate claims before such tests could be marketed 
(ibid).  Finally, the regulation would also provide that only medical professionals can 
order these tests.  Such a change in regulatory posture could effectively ban DTC in 
Europe (ibid.).  
Like the U.S., China has seen the emergence of a significant personal genomics 
industry, offering consumers both genetic testing for common health risks (especially 
neonatal screens), as well as more comprehensive genomic data (Jia, 2014).  It has been 
reported that many Chinese hospitals routinely offer genomic sequencing services to 
healthy patients during check-ups (ibid.)  The increasing popularity of personal genomic 
services in China has led Chinese regulators to take notice, and it is likely that greater 
scrutiny and regulation of the personal genomics market in China will soon arrive. 
Despite these moves toward greater regulation of DTC testing, there have also 
been calls for scaling back the initial precautionary approach taken by regulators in light 
of newer studies, which show that many of the public health concerns over DTC have not 
materialized (Vayena, 2013).  In a recent study, most participants in multiplex genetic 
susceptibility testing recalled their results correctly, did not interpret results in an overly 
deterministic way, and appreciated that genetics and behavior both contribute to disease 
risk (Kaphingst, 2012).  In another study, subjects who underwent DTC testing exhibited 
no measurable short-term changes in psychological health, diet and exercise behavior, or 
use of screening tests (Bloss, 2011). 
While commercial genomics itself knows no boundaries, and consumers from 
different parts of the world could potentially send their DNA samples to vendors based in 
other countries, until regulatory frameworks around the world catch up with the 
technology, the industry may need to self-regulate in the consumers’ interest (Gurwitz & 
Bregman-Eschet, 2009).  Whereas many laboratory-developed tests would arguably fall 
within the definition of a “device” that is subject to FDA regulation, there is a lack of 
data to support pre-market clearance, and the FDA cannot control off-label uses of these 
tests (McGuire, 2010).  Moreover, many DTC tests provide predictive and long-term 
information, whereas post-market surveillance may provide a better long-term strategy as 
long all tests are analytically valid, and all clinical claims are accurate and substantiated 
(ibid.).   
Additionally, typical DTC contracts include numerous legal disclaimers and 
limitations of liability (Phillips, 2015).  Most consumers lack the training to interpret 
these terms, or do not invest the time to do so.  While regulation may be necessary to 
protect consumer interests, in the short-term DTC companies can also improve the 
readability of their contracts and privacy policies to enhance consumer understanding and 
the consent process (ibid.).  The lessons learned in early adopter countries like the United 
States and several European nations are pertinent to consumers and companies around the 
world due to their impact on the availability and demand for DTC and other forms of 
genetic testing.  
 
Conclusion 
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 Over the past twenty-five years, the increasing speed and decreasing cost of 
genotyping and genome sequencing have led to the emergence of new business models 
based on providing genetic information directly to the public.  Genetic tests for individual 
diseases are widely available today in many developed countries at moderate cost, and 
are covered by many national and private insurance plans.  DTC genomic testing offered 
by 23andMe and similar providers has increased in popularity, but the medical value of 
these services remains to be proven.  Such services also face increasing governmental 
scrutiny and regulation, either as healthcare providers or diagnostic device vendors, 
making their future uncertain.  Whole genome sequencing, which will soon be broadly 
affordable, offers consumers a wealth of information, but much of the information that is 
delivered is not likely to be understood for years.  As such, the value of whole genome 
sequencing, as opposed to genotyping for known disease risks, remains questionable.   
 The global market for personal genomic products and services is likely to evolve 
rapidly over the next five to ten years.  DTC companies have responded to changes in the 
regulatory environment by emphasizing services like ancestry information to maintain 
their primary revenue streams.  Other companies have begun to offer interpretation-only 
services for personal genomics, which have not yet received the same level of scrutiny as 
similar services previously offered by DTC companies.  Finally, in addition to the 
primary market for these products, collaborations between DTC and major biotechnology 
and pharmaceutical companies could create secondary markets and augment their 
primary business models along the lines of 23andMe.  It is not clear which of today’s 
players, if any, will remain active in the future, or whether new players will enter the 
market from other sectors such as computing, information technology and online 
services, and whether early U.S. players will remain dominant in the face of market entry 
by competitors in China and elsewhere.  What is certain, however, is that the amount of 
genomic information available to the general public will continue to increase rapidly, and 
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